Logo

Scynexis Reports Results of Ibrexafungerp in P-III (CANDLE) Study for the Prevention of Recurrent Vaginal Yeast Infections

Share this
Scynexis Reports Results of Ibrexafungerp in P-III (CANDLE) Study for the Prevention of Recurrent Vaginal Yeast Infections

Scynexis Reports Results of Ibrexafungerp in P-III (CANDLE) Study for the Prevention of Recurrent Vaginal Yeast Infections

Shots:

  • The P-III (CANDLE) study evaluates ibrexafungerp (300mg, bid) vs PBO in 260 patients with rVVC. The results will submit to the US FDA in H1’22 with an expected approval at the end of 2022
  • The results showed that patients achieved clinical success with no recurrence in culture-proven, presumed, or suspected (65.4% vs 53.1%) @24wks., benefits were sustained over 3mos. follow-up period & remained significant while 2EPs were consistent with the results of primary analysis
  • Additionally, 71% reduction or elimination of signs & symptoms who failed to respond to a three-day regimen of fluconazole., was safe & well-tolerated with no SAEs & no discontinuation due to AEs

Ref: GlobeNewswire | Image: GlobeNewswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions